Precision Oncology: Leveraging Cancer Genomics for Tailored Treatments

Wanggor Berg^*
*Correspondence: Wanggor Berg, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy, Email:

Introduction

Cancer is a complex and heterogeneous disease characterized by uncontrolled cell growth and spread. Despite significant advancements in treatment, traditional cancer therapies, such as chemotherapy and radiation, often result in variable outcomes due to individual differences in genetics, tumor biology, and the environment. As a result, there is an increasing shift toward precision oncology, a personalized approach to cancer treatment that integrates detailed genetic information from both the patient and their tumor. Precision oncology aims to tailor therapies based on the specific genetic alterations found within an individual's cancer cells, ensuring more effective, targeted treatments and reducing unnecessary side effects. By leveraging cancer genomics-studying the genetic makeup of tumors-precision oncology holds the potential to revolutionize cancer care and significantly improve patient outcomes [1]. This article explores the role of cancer genomics in precision oncology, describing how genetic profiling is used to identify actionable mutations, the challenges in implementing genomic medicine, and the future directions of tailored cancer therapies.

Description

Cancer genomics involves analyzing the genetic mutations and alterations that drive the development and progression of cancer. Tumors often contain a unique set of genetic changes, which may include point mutations, deletions, amplifications, or chromosomal rearrangements. These mutations can affect genes that control critical cellular processes such as growth, apoptosis (cell death), DNA repair, and angiogenesis (formation of new blood vessels). By identifying these mutations, clinicians can gain insights into the tumor’s specific biology, including potential targets for therapy. The primary tool for cancer genomics is Next-Generation Sequencing (NGS), which allows comprehensive analysis of tumor DNA and RNA. NGS can identify mutations in driver genes (those that contribute directly to tumorigenesis) and passenger genes (which accumulate due to genetic instability but do not necessarily drive cancer progression). Additionally, techniques like Whole-Genome Sequencing (WGS), Whole-Exome Sequencing (WES), and RNA Sequencing (RNAseq) can provide a deeper understanding of the genetic and transcriptomic landscape of tumors [2].

The most promising aspect of cancer genomics is the identification of actionable mutations that can be targeted by specific drugs. Targeted therapies are designed to interfere with the molecular pathways that are dysregulated in cancer cells. For instance, if a patient’s tumor contains a mutation in the Epidermal Growth Factor Receptor (EGFR), a tyrosine kinase inhibitor like erlotinib or osimertinib may be used to block the signaling pathway, slowing or stopping tumor growth. The HER2 gene, which codes for a receptor protein involved in cell growth, is overexpressed in certain breast cancers. Drugs like trastuzumab (Herceptin) specifically target HER2, offering significant improvements in survival. About half of melanomas harbor mutations in the BRAF gene, particularly the V600E mutation. In such cases, BRAF inhibitors like vemurafenib can effectively target the mutant protein, leading to tumor shrinkage. Anaplastic Lymphoma Kinase (ALK) gene rearrangements are seen in a subset of NSCLC patients. Crizotinib and other ALK inhibitors have been shown to improve survival outcomes in patients with this mutation [2]. In addition to targeted therapies, cancer genomics also helps in the identification of genetic alterations that may make tumors susceptible to Immune Checkpoint Inhibitors (ICIs). For example, tumors with high mutational burden or Microsatellite Instability (MSI-H) may respond well to therapies like pembrolizumab, which targets the PD-1/PD-L1 immune checkpoint.

Despite the promise of precision oncology, several challenges remain in its widespread adoption and clinical implementation. Tumors are often heterogeneous, meaning that different regions of a tumor may have distinct genetic profiles. This complicates the interpretation of genomic data, as some mutations found in a biopsy may not be present in other parts of the tumor or may change over time (temporal heterogeneity). Comprehensive genomic testing can be expensive, and not all healthcare systems can afford to offer such testing to all patients. This may limit access to precision therapies, especially in low-resource settings [3]. Furthermore, the infrastructure required to interpret and act upon genomic data—such as bioinformatics support and trained oncologists-may not be universally available. Genomic data often contains vast amounts of information that must be carefully analyzed to identify clinically actionable mutations. Integrating this data with the patient's clinical history, other molecular profiles, and real-time treatment responses remains a significant challenge. Over time, even tumors that initially respond to targeted therapies may develop resistance through additional mutations. This phenomenon, known as acquired resistance, poses a major obstacle to the long-term success of precision oncology. Researchers are investigating ways to circumvent or overcome this resistance through combination therapies or next-generation targeted agents [4].

Liquid biopsies, which analyze tumor DNA from blood samples, offer a less invasive alternative to traditional tissue biopsies. Liquid biopsies may allow for real-time monitoring of tumor dynamics, enabling earlier detection of resistance mutations and adjustments to therapy. AI and machine learning algorithms are being used to analyze vast amounts of genomic, clinical, and imaging data. These technologies hold the potential to improve the accuracy of mutation detection, predict patient responses to treatment, and optimize therapeutic strategies. Researchers are increasingly exploring the combination of targeted therapies with immunotherapies, chemotherapy, and radiation. Such combinations may enhance the effectiveness of treatment, reduce resistance, and target multiple pathways involved in tumor progression. Another frontier in precision oncology is the development of personalized cancer vaccines. These vaccines aim to stimulate the immune system to target specific mutations present in an individual’s tumor, offering a highly tailored form of immunotherapy [5].

Conclusion

Precision oncology represents a transformative shift in cancer treatment, promising more effective, personalized therapies based on a detailed understanding of an individual’s tumor genomics. By identifying actionable mutations, clinicians can offer targeted treatments that increase the likelihood of successful outcomes while minimizing harm to healthy tissues. However, challenges such as tumor heterogeneity, cost, and resistance mechanisms need to be addressed for precision oncology to reach its full potential. Ongoing advancements in genomics, AI, liquid biopsy technologies, and immunotherapy will continue to drive the field forward, ultimately improving survival rates and quality of life for cancer patients worldwide. As our ability to decode the genetic underpinnings of cancer improves, the future of cancer treatment will increasingly be defined by individualized, data-driven strategies.

Acknowledgment

None.

Conflict of Interest

None.

References

1. He, Xiujing, Xiaowei Liu, Fengli Zuo and Hubing Shi, et al. "Artificial intelligence-based multi-omics analysis fuels cancer precision medicine." Semin Cancer Biol 88(2023):187-200.

Google Scholar, Crossref, Indexed at

2. Tran, Khoa A., Olga Kondrashova, Andrew Bradley and Elizabeth D. Williams, et al. "Deep learning in cancer diagnosis, prognosis and treatment selection." Genome Med 13 (2021): 1-17.

Google Scholar, Crossref, Indexed at

3. Severson, Tesa M., Yanyun Zhu, Stefan Prekovic and Karianne Schuurman, et al. "Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients." Medrxiv (2023): 2023-02.

Google Scholar, Crossref, Indexed at

4. Moore, Steven C., I-Min Lee, Elisabete Weiderpass and Peter T. Campbell et al. "Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults." JAMA Intern Med 176 (2016): 816-825.

Google Scholar, Crossref, Indexed at

5. Pedersen, Bente K. and Mark A. Febbraio. "Muscle as an endocrine organ: Focus on muscle-derived interleukin-6." Physiol Rev (2008).

Google Scholar, Crossref, Indexed at